In the 16th week of 2024, the electrocardiogram analysis artificial intelligence (AI) software “AiTiA LVSD” developed by the medical software development company “MedicalAI” was selected as the product of IR52 Jang Young Sil. This software uses AI technology to analyze electrocardiograms measured from patients and supports the diagnosis of left ventricular systolic dysfunction, a type of heart failure. If you input the patient’s electrocardiogram, it will tell you the probability of heart failure on a scale of 0 to 100.
Heart failure is a disease in which the heart’s function declines, resulting in insufficient blood supply to every part of the body. Many people with various heart diseases progress to heart failure, also known as the “endpoint of heart disease.” The five-year survival rate is only 55 percent.
Heart disease is usually diagnosed by an electrocardiogram. An electrocardiogram is a quick and inexpensive test that measures the electricity produced in the skin when the heart beats. However, electrocardiogram alone cannot diagnose heart failure. An echocardiogram or less accurate blood tests had to be performed.
Kwon Jun-myung, CEO of medical AI at Seoul National University School of Medicine, said, “Diagnosing heart failure using an electrocardiogram alone is beyond human reading comprehension,” and added, “We are developing AI to be able to diagnose heart failure within 10 seconds using an electrocardiogram alone.” introduced,” he said. alone. “The diagnostic accuracy of AiTiA LVSD reaches 91.9%. Considering that the accuracy of the blood test is 72.0%, it is more reliable.
AiTiA LVSD will be introduced at Bucheon Sejong Hospital and Incheon Sejong Hospital Health Examination Center from May. The company explained that it is currently being used under contract with major advanced general hospitals, and is expected to be used in more than 200 hospitals by the end of the year. It was designated as an innovative medical technology by the Korea Medical Research Institute in 2023, and can be prescribed free of charge.
Heart failure is broadly classified into LVSD, which is caused by a decline in left ventricular contractile function, and problems with left ventricular relaxation function. AiTiA LVSD diagnoses her LVSD. Medical AI is already developing software for heart failure rather than LVSD, which is expected to be approved by the Ministry of Food and Drug Safety next year.
CEO Kwon said, “Heart failure often presents with ambiguous symptoms, making early diagnosis difficult. We will not miss the prime time for treatment through ‘AiTiA LVSD,’ which can easily check for heart failure.”

Sponsored by the Ministry of Science, Technology and Communication: Mainichi Keizai Shimbun, Korea Industrial Technology Promotion Association
[Reporter Ko Jaewon]